The basal phenotype of BRCA1-related breast cancer: past, present and future.
about
Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancersDNA double-strand break repair pathway choice and cancerDistant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients.Hereditary breast cancer: ever more pieces to the polygenic puzzle.Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.Epidemiology of basal-like breast cancer.p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancerc-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression.Correlation between CpG methylation profiles and hormone receptor status in breast cancers.The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.Clinical and pathologic aspects of basal-like breast cancers.EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy.Recent trends in breast cancer among younger women in the United States.Impact of hyperhomocysteinemia on breast cancer initiation and progression: epigenetic perspective.High prevalence of triple-negative tumors in an urban cancer center.A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard.Identification of women with an increased risk of developing radiation-induced breast cancer.P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.Tissue microarrays for testing basal biomarkers in familial breast cancer cases.Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67.A comprehensive catalogue of functional genetic variations in the EGFR pathway: protein-protein interaction analysis reveals novel genes and polymorphisms important for cancer research.Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade.Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer.BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers.DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients.CDKN2A-positive breast cancers in young women from Poland.
P2860
Q21260381-F11A6576-CC20-4E66-87B4-9A0D318CCE95Q26996175-5602C370-A0E5-469D-BC02-DFC97543E77FQ33303403-D04F59C8-CA7C-44C9-B494-CB75C4173105Q33356511-FF52E3A9-F9B9-4E8C-A7AF-0A93CC213878Q33780945-6708FB43-5EE2-4C47-B919-1B26696F98C9Q34081324-24A52667-1CC5-43C5-8249-4DD874791079Q34639174-60ED3416-00C8-4D22-B1B6-D751003A47F2Q34887682-1AD829CA-D4FE-4D93-862B-8B522ADF2CBFQ35828457-E85DDCC5-64D3-4B09-BA56-AFC4644E4D37Q36393321-477F9BCD-04D9-4437-AC0E-F01C09E5B3F1Q36627600-EC5B0347-A5F1-4C0B-B1EF-DB2D13316227Q37062876-5BF58FAD-8D90-4A30-90D3-BEB44BE9C9A3Q37206247-A8E25A96-B297-4B2B-ABFF-0BF839686B0CQ37289051-CFA51C10-F646-4D14-A68A-BA5AF0D5C4D3Q39112249-0510AE58-3D0D-47AC-9697-F2386FB55600Q39846699-C9D6EA91-5EFE-445E-8CE2-8D5E4FB21A6FQ42438922-4537F1D6-F7D1-46EE-BB92-EE0221A2D1A8Q42468035-C0AE1036-12F2-4ACF-A6B0-D8BCFF943A3CQ42504546-C2170814-D420-4747-908D-D1997533ADB5Q42521314-914A3AC4-7DAF-477B-BE9A-16F93ADD9847Q42522379-A4F3CFDA-BB97-4449-8671-8CEF2339D058Q42522644-4ECA75D1-4900-42FA-80B9-B30B0F4B7DC3Q43416110-16417267-07A2-43E7-B4B8-E25325B38FA1Q45372716-E49908B9-2A27-4669-A77C-9D5BADFA66EAQ50485878-B390DB6B-AAA6-4E34-ADD5-72C0075B801CQ51293206-CCECFECE-0021-42C4-A468-F384EE869631Q53563482-253F018E-AD8C-45DF-ADD5-2C8C0F8DEE4FQ54303001-72E011D7-A581-48D5-9A40-CE1A34E37A16Q54574835-33EF24AD-5722-45A0-8AE7-B523B9DBEC15
P2860
The basal phenotype of BRCA1-related breast cancer: past, present and future.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The basal phenotype of BRCA1-related breast cancer: past, present and future.
@ast
The basal phenotype of BRCA1-related breast cancer: past, present and future.
@en
type
label
The basal phenotype of BRCA1-related breast cancer: past, present and future.
@ast
The basal phenotype of BRCA1-related breast cancer: past, present and future.
@en
prefLabel
The basal phenotype of BRCA1-related breast cancer: past, present and future.
@ast
The basal phenotype of BRCA1-related breast cancer: past, present and future.
@en
P356
P1433
P1476
The basal phenotype of BRCA1-related breast cancer: past, present and future.
@en
P2093
Marc D Tischkowitz
P304
P356
10.4161/CC.5.9.2713
P577
2006-05-01T00:00:00Z